Immunocore Holdings PLC ADR
Open
32.65 -1.15
Overview
Share price change
24h
Min
32.1
Max
33.58
Income | 43M 13M |
|---|---|
Sales | 29M 107M |
EPS | 0.25 |
Profit margin | 12.139 |
Employees | 524 |
EBITDA | 25M 17M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +111.53% upside |
Next Earnings | 6 sie 2026 |
|---|
Market Cap | 200M 1.6B |
|---|---|
Previous open | 33.8 |
Previous close | 32.65 |
Immunocore Holdings PLC ADR Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Immunocore Holdings PLC ADR Forecast
Price Target
By TipRanks
111.53% upside
12 Months Forecast
Average 68.6 USD 111.53%
High 100 USD
Low 35 USD
Based on 6 Wall Street analysts offering 12 month price targets forImmunocore Holdings PLC ADR - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Immunocore Holdings PLC ADR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
